title: A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment.
abstract: Multiple myeloma is an incurable and slow growing plasma cell neoplasm. The introduction of new drugs has increased the number of treatment options. Bortezomib, the first-in-class proteasome inhibitor, has been shown to have a significant antitumor activity in the treatment of relapse/refractory patients with multiple myeloma. Additionally, plasmacytomas have shown significant response to bortezomib. In this case report, we describe a patient who developed disseminated and fulminant extramedullary plasmacytomas during combination chemotherapy treatment with bortezomib within a short period, after having shown clinical improvement.
authors.affiliation: Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
authors.forename: Soo-Young
authors.initials: SY
authors.lastname: Bae
authors.forename: Jae-Sook
authors.initials: JS
authors.lastname: Ahn
authors.forename: Deok-Hwan
authors.initials: DH
authors.lastname: Yang
authors.forename: Yeo-Kyeoung
authors.initials: YK
authors.lastname: Kim
authors.forename: Jung-Joon
authors.initials: JJ
authors.lastname: Min
authors.forename: Ho-Chun
authors.initials: HC
authors.lastname: Song
authors.forename: Hee-Seung
authors.initials: HS
authors.lastname: Bom
authors.forename: Yong Yeon
authors.initials: YY
authors.lastname: Jeong
authors.forename: Hyeoung-Joon
authors.initials: HJ
authors.lastname: Kim
authors.forename: Je-Jung
authors.initials: JJ
authors.lastname: Lee